HealthFinSMEsabout 1 hour ago
Neurosterix Raises $105M Series B Funding
1 min read
Neurosterix, a biotechnology company based in Geneva and Boston, raised $105M in Series B funding led by RTW Investments. The company plans to use the capital to advance its lead clinical-stage program, NTX-253, into Phase 2 development for schizophrenia. The round also includes participation from Janus Henderson Investors, GV, and other investors.
Level
Hype check
Tap to vote and see what everyone thinks.